Ann: GENERAL: PEB: Cxbladder User Program with Kaiser Permanente...

• Release Date: 22/06/15 11:56
• Summary: GENERAL: PEB: Cxbladder User Program with Kaiser Permanente Commences
• Price Sensitive: No
• Download Document  5.36KB

					PEB
22/06/2015 11:56
GENERAL
NOT PRICE SENSITIVE
REL: 1156 HRS Pacific Edge Limited

GENERAL: PEB: Cxbladder User Program with Kaiser Permanente Commences

22 June 2015

Cxbladder User Program with Kaiser Permanente Southern California commences
recruitment of patients

Pacific Edge Ltd advises that the User Program Research with Southern
California Permanente Medical Group (SCPMG) to evaluate  its bladder cancer
technology Cxbladder within the clinical settings of Kaiser Permanente's
health care network has commenced recruitment of patients.

Operating in eight states, Kaiser Permanente is one of America's leading
health care providers with a not-for-profit health plan. With their provision
of services to 9.5 million people, Kaiser Permanente cares for a population
twice the size of all of New Zealand's district health boards.

The Kaiser Permanente User Program research project is planned to recruit
approximately 2000 patients presenting with microscopic and macroscopic
hematuria (blood in the urine), from the 3.7 million members of Kaiser
Permanente Southern California.

The User Program research will conclude late this year or early 2016 if
recruitment meets planned schedules.

Pacific Edge Chief Executive David Darling says User Programs are a key part
of the adoption process where customers are able to obtain data and specific
experience of the benefits of using the Cxbladder technology in their own
clinical settings.

"Cxbladder Triage  is targeted to provide clinicians with a means to identify
patients, with a high degree of surety who do not have bladder cancer. It is
anticipated that significant advantages will accrue to both the patient and
the health care provider from the successful integration of Cxbladder into
the  clinical setting. Typically less than 5 per cent of those patients who
present to their clinician with microscopic hematuria (non-visible blood in
urine of clinical significance) will be diagnosed with bladder cancer and
approximately 12 per cent of those patients who present with visible blood in
their urine.  At present nearly all patients with hematuria are currently
required to have an expensive clinical work-up to identify those requiring
further investigation."

User Program samples collected in Cxbladder's proprietary urine sampling
system will be sent to PEDUSA, the company's purpose built laboratory in
Hershey, Pennsylvania for the laboratory analysis.

Pacific Edge Diagnostic USA, CEO Jackie Walker says "Kaiser Permanente is
well regarded in the medical community for providing the highest standards
of health care for its members through development and early adoption of
industry leading technology".

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

ABOUT Cxbladder Triage

Cxbladder Triage is a novel molecular test that combines the power of the
genomic biomarkers with extra phenotypic and clinical risk factors to
accurately identify and remove patients with hematuria who have a low
probability of bladder cancer, from needing to have a full-urological
work-up. This is a tool for use by clinicians and physicians in the primary
evaluation and is intended to reduce of the number of patients needing an
expensive and invasive work-up for urothelial cancer.

www.cxbladder.com

ABOUT Cxbladder Detect

Cxbladder Detect is a proprietary, accurate molecular diagnostic test that
enables the non-invasive detection of bladder and other urinary tract cancers
from a small volume of urine. Cxbladder Detect is commercially available in
New Zealand, Australia and the USA.  Cxbladder Detect is available in the USA
and NZ as a laboroatory Developed Test (LDT) from the company's CLIA
certified laboratories, providing physicians and clinicians with a quick,
cost effective and accurate measure of the presence of the cancer, and
provides urologists with an effective adjunct to cystoscopy. The Cxbladder
Detect cancer detection test has been validated by a multicentre,
international clinical study.

www.cxbladder.com

ABOUT Bladder Cancer

Globally, bladder cancer has the 9th highest incidence and the 4th highest
incidence for men. One of the early symptoms of bladder cancer is the
presence of blood in the urine, haematuria. People with haematuria often
present to their general practitioner before being referred on to a
urologist. Bladder cancer has a very high recurrence rate of approximately
50%-70% with up to 30% of these recurring as later stage tumours. However,
bladder cancers are highly treatable, especially if detected in the early
stages when there is a much higher probability of survival.  Timely detection
and regular surveillance and monitoring of this cancer is a key element of
the clinical process and of the individual's annual healthcare plan.

ABOUT Pacific Edge

Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
company specialising in the discovery and commercialisation of diagnostic and
prognostic technology for the early detection and monitoring of cancer. The
company is developing and commercialising its range of Cxbladder bladder
cancer tests. It's first commercial product, Cxbladder Detect, is now being
actively marketed to physicians and clinicians in New Zealand, Australia, and
the USA through the company's wholly owned subsidiaries and selected
commercial partners.

www.pacificedge.co.nz www.pacificedgedx.com
End CA:00265987 For:PEB    Type:GENERAL    Time:2015-06-22 11:56:19